What is Ziconotide?
Ziconotide (brand name PRIALT, development codes SNX-111 / ω-MVIIA) is a synthetic version of the ω-conotoxin MVIIA peptide originally isolated from the venom of the marine cone snail Conus magus. It was approved by the FDA on December 28, 2004 as the first non-opioid intrathecal analgesic for severe chronic pain, and it remains the canonical example of a venom-derived peptide drug in clinical use.
The cone snail produces ω-MVIIA as part of its prey-immobilization venom; the same N-type calcium channel block that paralyzes small fish creates analgesia when delivered to the human spinal cord at sub-paralytic doses.
Structure and Origin
Sequence: CKGKGAKCSRLMYDCCTGSCRSGKC-NH2 — 25 amino acids, three intramolecular disulfide bonds (Cys1-Cys16, Cys8-Cys20, Cys15-Cys25), C-terminal amidation.
Conotoxins are characterized by their inhibitor cystine knot (ICK) motif — a small, rigid scaffold defined by three disulfide bonds in a characteristic topology. This structural framework is exceptionally stable and underlies the appeal of conotoxin scaffolds in drug discovery.
Ziconotide is identical in sequence and stereochemistry to natural ω-MVIIA; it is produced by solid-phase peptide synthesis followed by oxidative folding.
Mechanism of Action
- Selective N-type (Cav2.2) voltage-gated calcium channel blockade — ziconotide binds to the extracellular pore region of N-type channels with high selectivity over L-, P/Q-, R-, and T-type channels
- Presynaptic terminal action — N-type channels mediate calcium influx that drives neurotransmitter release at presynaptic terminals of nociceptive primary afferent neurons in the dorsal horn
- Reduced release of glutamate, substance P, and CGRP — by blocking calcium entry, ziconotide reduces release of pain-signaling neurotransmitters at the first central synapse of the nociceptive pathway
- Spinal-cord-specific delivery — because ziconotide does not cross the blood-brain barrier and is rapidly cleared from systemic circulation, it must be delivered intrathecally via implanted pump
The mechanism is completely independent of opioid receptors, so ziconotide retains efficacy in opioid-tolerant patients and produces no respiratory depression or addiction.
Clinical Evidence
Ziconotide has been studied in patients with severe chronic pain refractory to systemic opioids and intrathecal morphine. The pivotal trials demonstrated:
- Significant reductions in Visual Analog Scale of Pain Intensity (VASPI)
- Effective in cancer pain, neuropathic pain, and post-surgical pain refractory to other modalities
- Long-term open-label studies show sustained efficacy over years of treatment
Approval History
- December 28, 2004 — FDA approval for severe chronic pain in patients for whom intrathecal therapy is warranted and other therapies have failed or been intolerable
- April 2005 — EMA approval
Place in Therapy
Ziconotide is reserved for severe chronic pain that has failed conventional therapy including intrathecal opioids. It is delivered via an implanted intrathecal pump, with very slow titration to manage neuropsychiatric side effects. Because of dosing complexity, it is used almost exclusively at specialized pain centers.
It is one of the few non-opioid, non-anesthetic options for severe chronic pain — particularly valuable in patients with opioid intolerance, addiction history, or cancer-related pain inadequately controlled by other agents.
Safety Profile
Ziconotide's narrow therapeutic index requires careful titration. The most concerning adverse events are neuropsychiatric:
- Confusion, hallucinations, psychosis
- Mood changes including depression and suicidality
- Dizziness, ataxia, abnormal gait
- Memory impairment
The label carries a boxed warning for severe psychiatric symptoms and neurological impairment. These effects are reversible with dose reduction or discontinuation. Other adverse events include nausea, asthenia, and elevated creatine kinase.
Why It Matters
Ziconotide is the first-in-class peptide drug from a venom source and remains an important reference compound in marine natural product drug discovery. The peptide-conotoxin scaffold has spawned an extensive research pipeline, including additional N-type, P/Q-type, and α-conotoxin candidates for various pain and neurologic indications.